Psychopharmacology the fourth generation of progress: An official publication of the American college of neuropsychopharmacology

Başlık:

ISBN:

9780781701662

Yayın Bilgisi:

New York : Raven Press , 1995.

Fiziksel Tanım:

2002 s. ; 28 sm.

Özet:

PHYSPHARMACOLOGY-FOYD E. BLOOM- Contents CONTRIBUTORS .............................................................. xix PREFACE TO THE THIRD EDITION ............................................. xli PREFACE .................................................................... xliii PARTI. PRECLINICAL SECTION 1. Introduction to Preclinical Neuropsychopharmacology ................ 1 Floyd E. Bloom Critical Analysis of Methods 2. Basic Concepts and Techniques of Molecular Genetics ............... 9 Samuel H. Barondes 3. Cytology and Circuitry ............................................... 13 Stanley J. Watson, Jr. and William E. Cullinan 4. A Critical Analysis of Neurochemical Methods for Monitoring Transmitter Dynamics in the Brain ................................... 29 Janet M. Finlay and Michael J. Zigmond 5. Electrophysiology .................................................... 41 Gary S. Aston-Jones and George R. Siggins 6. Behavioral Techniques in Preclinical Neuropsychopharmacology Research ............................................................. 65 James E. Barrett and Klaus A. Miczek Transmitter Systems Amino Acids 7. Excitatory Amino Acid Neurotransmission ........................... 75 Carl W. Cotman, Jennifer S. Kahle, Stephan E. Miller, Jolanta Was, and Richard J. Bridges 8. GABA and Glycine .................................................. 87 Steven M. Paul Amines 9. Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for Central Nervous System Therapeutics ................................ 95 Stephen P. Arneric, James P. Sullivan, and Michael Williams 10. Molecular Biology, Pharmacology, and Brain Distribution of Subtypes of the Muscarinic Receptor ................................. Ill Frederick J. Ehlert, William R. Roeske, and Henry I. Yamamura 11. Cholinergic Transduction ............................................ 125 Elliott Richelson 12. Structure and Function of Cholinergic Pathways in the Cerebral Cortex, Limbic System, Basal Ganglia, and Thalamus of the Human Brain ........................................................ 135 Marek-Marsel Mesulam 13. Functional Heterogeneity of Central Cholinergic Systems ............ 147 Peter B. Reiner and H. Christian Fibiger 14. Molecular Biology of the Dopamine Receptor Subtypes .............. 155 Olivier Civelli 15. Electrophysiological Properties of Midbrain Dopamine Neurons ...... 163 Anthony A. Grace and Benjamin S. Bunney 16. The Dopamine Transporter: Potential Involvement in Neuropsychiatric Disorders ........................................... 179 Michael J. Bannon, James G. Granneman, and Gregory Kapatos 17. Long- and Short-Term Regulation of Tyrosine Hydroxylase .......... 189 Menek Goldstein 18. Colocalization in Dopamine Neurons ................................. 197 Ariel Y. Deutch and Andrew J. Bean 19. Dopamine Receptor Expression in the Central Nervous System ....... 207 Alfred Mansour and Stanley J. Watson, Jr. 20. Dopamine Autoreceptor Signal Transduction and Regulation ......... 221 Louis A. Chiodo, Arthur S. Freeman, and Benjamin S. Bunney 21. Biochemical Pharmacology of Midbrain Dopamine Neurons .......... 227 Robert H. Roth and John D. Elsworth 22. Dopaminergic Neuronal Systems in the Hypothalamus ............... 245 Kenneth E. Moore and Keith J. Lookingland 23. Electron Microscopy of Central Dopamine Systems .................. 257 Virginia M. Pickel and Susan R. Sesack 24. Development of Mesencephalic Dopamine Neurons in the Nonhuman Primate: Relationship to Survival and Growth Following Neural Transplantation ...................................................... 269 John R. Sladek, Jr., Barbara Blanchard, T. J. Collier, John D. Elsworth, Jane R. Taylor, Robert H. Roth, and D. Eugene Redmond, Jr. 25. Mesocorticolimbic Dopaminergic Neurons: Functional and Regulatory Roles ................................................................ 283 Michel Le Moal 26. Dopamine Receptors: Clinical Correlates ............................. 295 Philip Seeman 27. Signal Transduction Pathways for Catecholamine Receptors .......... 303 Ronald S. Duman and Eric J. Nestler 28. Norepinephrine and Serotonin Transporters: Molecular Targets of Antidepressant Drugs ................................................ 321 Eric L. Barker and Randy D. Blakely 29. Pharmacology and Physiology of Central Noradrenergic Systems ..... 335 Stephen L. Foote and Gary S. Aston-Jones 30. Coexisting Neurotransmitters in Central Noradrenergic Neurons ...... 347 Philip V. Holmes and Jacqueline N. Crawley 31. Modification of Central Catecholaminergic Systems by Stress and Injury: Functional Significance and Clinical Implications ............. 355 Elizabeth D. Abercrombie and Michael J. Zigmond 32. Central Norepinephrine Neurons and Behavior ....................... 363 Trevor W. Robbins and Barry J. Everitt 33. Physiological and Anatomical Determinants of Locus Coeruleus Discharge: Behavioral and Clinical Implications ...................... 373 Rita J. Valentino and Gary S. Aston-Jones 34. Noradrenergic Neural Substrates for Anxiety and Fear: Clinical Associations Based on Preclinical Research .......................... 387 Dennis S. Charney, J. Douglas Bremner, and D. Eugene Redmond, Jr. 35. Histamine ............................................................ 397 Jean-Charles Schwartz, Jean-Michel Arrang, Monique Garbarg, and Elisabeth Traiffort 36. Molecular Biology of Serotonin Receptors: A Basis for Understanding and Addressing Brain Function ....................... 407 Jean Chen Shih, Kevin J.-S. Chen, and Timothy K. Gallaher 37. Serotonin Receptor Subtypes ......................................... 415 Richard A. Glennon and Malgorzata Dukat 38. Serotonin Receptors: Signal Transduction Pathways .................. 431 Elaine Sanders-Bush and Herve Canton 39. Anatomy, Cell Biology, and Plasticity of the Serotonergic System: Neuropsychopharmacological Implications for the Actions of Psychotropic Drugs .................................................. 443 Efrain C. Azmitia and Patricia M. Whitaker-Azmitia 40. Electrophysiology of Serotonin Receptor Subtypes and Signal Transduction Pathways ............................................... 451 George K. Aghajanian 41. Serotonin and Behavior: A General Hypothesis ....................... 461 Barry L. Jacobs and Casimir A. Fornal 42. Indoleamines: The Role of Serotonin in Clinical Disorders ........... 471 George R. Heninger Peptides 43. General Overview of Neuropeptides .................................. 483 Tomas G. M. Hökfelt, Marie-Noelle Castel, Patrizia Marino, Xu Zhang, and Ake Dagerlind 44. Thyrotropin-Releasing Hormone: Focus on Basic Neurobiology ...... 493 George A. Mason, James C. Garbutt, and Arthur J. Prange, Jr. 45. Corticotropin-Releasing Factor: Physiology, Pharmacology, and Role in Central Nervous System and Immune Disorders ................... 505 Errol B. De Souza and Dimitri E. Grigoriadis 46. Neuropharmacology of Endogenous Opioid Peptides ................. 519 John J. Wagner and Charles I. Chavkin 47. Vasopressin and Oxytocin in the Central Nervous System ............ 531 Linda Rinaman, Thomas G. Sherman, and Edward M. Stricker 48.

Neuropeptide Y and Related Peptides ................................ 543 Claes Wahlestedt and Markus Heilig 49. Somatostatin in the Central Nervous System ......................... 553 David R. Rubinow, Candace L. Davis, and Robert M. Post 50. Galanin: A Neuropeptide with Important Central Nervous System Actions .............................................................. 563 Tamas Bartfai 51. The Neurobiology of Neurotensin .................................... 573 Garth Bissette and Charles B. Nemeroff 52. Cholecystokinin/Gastrin .............................................. 585 Margery C. Beinfeld New Transmitters 53. Arachidonic Acid .................................................... 595 Daniele Piomelli 54. Nitric Oxide and Related Substances as Neural Messengers .......... 609 Solomon H. Snyder and Ted M. Dawson 55. Neuronal Growth and Differentiation Factors and Synaptic Plasticity ... 619 Paul H. Patterson 56. Proto-Oncogenes: Beyond Second Messengers ....................... 631 James I. Morgan and Thomas E. Curran 57. Purinoceptors in Central Nervous System Function: Targets for Therapeutic Intervention ............................................. 643 Michael Williams Integrative Concepts 58. Brain Energy Metabolism: An Integrated Cellular Perspective ........ 657 Pierre J. Magistretti, Luc Pellerin, and Jean-Luc Martin 59. Molecular and Cellular Mechanisms of Brain Development .......... 671 David A. Morilak, Matthew H. Porteus, and Roland D. Ciaranello 60. The Development of Brain and Behavior ............................. 683 Thomas R. Insel 61. Intracellular Messenger Pathways as Mediators of Neural Plasticity .... 695 Eric J. Nestler and Ronald S. Duman 62. Neuroendocrine Interactions .......................................... 705 Bruce S. McEwen 63. Interactions Between the Nervous System and the Immune System: Implications for Psychopharmacology ................................ 719 Adrian J. Dunn 64. Adaptive Processes Regulating Tolerance to Behavioral Effects of Drugs ................................................................ 733 Alice M. Young and Andrew J. Goudle 65. The Psychopharmacology of Sexual Behavior ........................ 743 James G. Pfaus and Barry J. Everitt 66. Animal Models of Drug Addiction ................................... 759 George F. Koob 67. Stress ................................................................ 773 Huda A. Akil and M. Ines Morano 68. Animal Models of Psychiatric Disorders ............................. 787 Mark A. Geyer and Athina Markou 69. Genetic Strategies in Preclinical Substance Abuse Research .......... 799 John C. Crabbe, Jr. and Ting-Kai Li PART II. CLINICAL SECTION 70. Introduction to Clinical Neuropsychopharmacology ................... 813 David J. Kupfer Critical Analysis of Methods 71. The DSM-IV Classification and Psychopharmacology ................ 823 Alien Frances, Avram H. Mack, Ruth Ross, and Michael B. First 72. Clinical Study Design—Critical Issues ............................... 829 Donald S. Robinson and Robert F. Prien 73. Short- and Long-Term Psychopharmacological Treatment Strategies .. 839 Ira D. Click, David L. Braff, and David S. Janowsky 74. Pharmacokinetics and Pharmacodynamics ............................ 849 David J. Greenblatt, Jerold S. Harmatz, Lisa L. von Moltke, and Richard I. Shader 75. Methodological Issues in the Neuropathology of Mental Illness ....... 859 Joel E. Kleinman, Thomas M. Hyde, and Mary M. Herman 76. Positron and Single Photon Emission Tomography: Principles and Applications in Psychopharmacology ................................. 865 Robert T. Malison, Marc Lamelle, and Robert B. Innis 77. In Vivo Structural Brain Assessment ................................. 881 Kelvin O. Lim, Margaret Rosenbloom, and Adolf Pfefferbaum 78. Methodological Issues in Event-Related Brain Potential and Magnetic Field Studies ......................................................... 895 Walton T. Roth, Judith M. Ford, Adolf Pfefferbaum, and Thomas R. Elbert Psychiatrie Disorders Mood Disorders 79. Recent Studies on Norepinephrine Systems in Mood Disorders ....... 911 Alan F. Schatzberg and Joseph J. Schildkraut 80. Dopaminergic Mechanisms in Depression and Mania ................. 921 Paul Willner 81. The Serotonin Hypothesis of Major Depression ...................... 933 Michael Maes and Herbert Y. Meltzer 82. The Role of Acetylcholine Mechanisms in Mood Disorders .......... 945 David S. Janowsky and David H. Overstreet 83. Neuroendocrinology of Mood Disorders .............................. 957 Florian Holsboer 84. Neuropeptide Alterations in Mood Disorders ......................... 971 Paul M. Plotsky, Michael J. Owens, and Charles B. Nemeroff 85. Psychoneuroimmunology of Depression .............................. 983 Michael Irwin 86. Biological Rhythms in Mood Disorders .............................. 999 Anna Wirz-Justice 87. Brain Imaging in Mood Disorders .................................... 1019 Godfrey D. Pearlson and Thomas E. Schlaepfer 88. Mood Disorders Linked to the Reproductive Cycle in Women ........ 1029 Barbara L. Parry 89. Selective Serotonin Reuptake Inhibitors in the Acute Treatment of Depression ........................................................... 1043 Stuart A. Montgomery 90. Short-Term Treatment of Mood Disorders With Standard Antidepressants ...................................................... 1053 Michael J. Burke and Sheldon H. Preskorn 91. Long-Term Treatment of Mood Disorders ............................ 1067 Robert F. Prien and James H. Kocsis 92. Treatment-Resistant Depression ...................................... 1081 Michael E. Thase and A. John Rush 93. Lithium and the Anticonvulsants in the Treatment of Bipolar Disorder ............................................................. 1099 Joseph R. Calabrese, Charles Bowden, and Mark J. Woyshville 94. Psychosocial Predictors of Outcome in Depression ................... 1113 Robert M. A. Hirschfeld 95. Electroconvulsive Therapy ........................................... 1123 Harold A. Sackeim, D. P. Devanand, and Mitchell S. Nobler 96. Novel Pharmacological Approaches to the Treatment of Depression .. 1143 Dennis L. Murphy, Philip B. Mitchell, and William Z. Potter 97. The Neurobiology of Treatment-Resistant Mood Disorders ........... 1155 Robert M. Post and Susan R. B. Weiss Schizophrenia 98. Neurodevelopmental Perspectives on Schizophrenia .................. 1171 Daniel R. Weinberger 99. Functional Brain-Imaging Studies in Schizophrenia ................... 1185 Raquel E. Gur 100. New Developments in Dopamine and Schizophrenia ................. 1193 Rene S. Kahn and Kenneth L. Davis 101. Schizophrenia and Glutamate ........................................ 1205 Blynn Garland Bunney, William E. Bunney, Jr., and Arvid Carlsson 102. The Role of Serotonin in Schizophrenia .............................. 1215 Bryan L. Roth and Herbert Y. Meltzer 103. The Effects of Neuroleptics on Plasma Homovanillic Acid ........... 1229 Arnold J. Friedhoff and Raul R. Silva 104. Neurophysiological and Psychophysiological Approaches to Schizophrenia ........................................................ 1235 Keith H.

Nuechterlein and Michael E. Dawson 105. Neurocognitive Functioning in Patients with Schizophrenia: An Overview ............................................................ 1245 Terry E. Goldberg and James M. Gold 106. Acute Treatment of Schizophrenia ................................... 1259 William C. Wirshing, Stephen R. Marder, Theodore Van Putten, and Donna Ames 107. Maintenance Drug Treatment for Schizophrenia ...................... 1267 John G. Csernansky and John G. Newcomer 108. Atypical Antipsychotic Drugs ........................................ 1277 Herbert Y. Meltzer Anxiety Disorders 109. Neuroimaging Studies of Human Anxiety Disorders: Cutting Paths of Knowledge through the Field of Neurotic Phenomena ................ 1287 Lewis R. Baxter, Jr. 110. Anxiety and Serotonin1A Receptor .................................... 1301 Jeremy D. Coplan, Susan I. Walk, and Donald F. Klein 111. Pharmacological Challenges in Anxiety Disorders .................... 1311 Lawrence H. Price, Andrew W. Goddard, Linda C. Barr, and Wayne K. Goodman 112. Environmental Factors in the Etiology of Anxiety .................... 1325 Karrie J. Craig, Kelly J. Brown, and Andrew Baum 113. The Pharmacotherapy of Acute Anxiety: A Mini-Update ............. 1341 Richard I. Shader and David J. Greenblatt 114. Issues in the Long-Term Treatment of Anxiety Disorders ............ 1349 Edward Schweizer, Karl Rickeis, and Eberhard H. Uhlenhuth Geriatrie Disorders I 115. Towards an Understanding of the Genetics of Alzheimer’s Disease ... 1361 j Corinne L. Lendon and Alison M. Goate

Methodological and Statistical Progress in Psychiatric Clinical Research: A Statistician’s Perspective ................................ 1849 Helena Chmura Kraemer PART III. SPECIAL TOPICS 158. New Drag Design in Psychopharmacology: The Impact of Molecular Biology .............................................................. 1861 John F. Tollman and Svein G. Dahi 159. Ethical Issues in Genetic Screening and Testing, Gene Therapy, and Scientific Conduct ................................................... 1875 Lisa S. Parker and Elizabeth Gettig 160. The Economics of Psychotropic Drag Development .................. 1883 Joseph A. DiMasi and Louis Lasagna 161. Economic Evaluation of Drag Treatment for Psychiatric Disorders: The New Clinical Trial Protocol ..................................... 1897 Gary A. Zarkin, Henry G. Grabowski, Josephine Mauskopf, Heather A. Bannerman, and Richard H. Weisler

Konu Terimi:

Psikofarmakoloji

Farmakoloji

Mevcut:*

Library	Materyal Türü	Barkod	Yer Numarası	Durumu/İade Tarihi
Arıyor... Ferit Melen Library	Book	049750	615.78 PSY 1995 k.1	Arıyor... Unknown

Mevcut:*

On Order